Amicus Therapeutics

Quarterly Financials

Values in thousands 2024-06-30 2024-03-31 2023-12-31 2023-09-30
Revenue
$126,669
$110,403
$115,082
$103,501
Gross Profit
113,226
94,682
101,576
93,555
EBITDA
17,149
-19,522
-1,510
-29,207
EBIT
14,967
-21,676
-3,692
-31,435
Net Income
-15,697
-48,419
-33,843
-21,577
Net Change In Cash
126,669
110,403
115,082
103,501
Free Cash Flow
21,593
-31,506
1,727
-39,912
Cash
209,335
209,761
246,994
263,320
Basic Shares
303,773
302,903
293,594
295,759

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$399,356
$329,233
$305,514
$260,886
Gross Profit
354,157
290,634
271,048
229,842
EBITDA
-65,620
-191,884
-196,103
-232,563
EBIT
-73,493
-197,226
-202,312
-241,409
Net Income
-151,584
-236,568
-250,460
-276,852
Net Change In Cash
399,356
329,233
305,514
260,886
Cost of Revenue
-81,722
88,343
15,989
Free Cash Flow
-76,531
-170,341
-206,375
-236,517
Cash
246,994
148,813
245,197
163,240
Basic Shares
295,164
289,057
271,421
258,867

Earnings Calls

Quarter EPS
2024-06-30
-$0.05
2024-03-31
-$0.16
2023-12-31
-$0.11
2023-09-30
-$0.07